This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal application in subjects with common warts.

开始日期2026-10-01

申办/合作机构

Verrica Pharmaceuticals, Inc.

[+2]

NCT07637734

/ Recruiting临床3期

COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

开始日期2026-06-15

申办/合作机构

Verrica Pharmaceuticals, Inc.

[+5]

NCT07457918

/ Recruiting临床3期

COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are:
* To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs).
* To evaluate the efficacy of continued skin application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments.
Participants with eligible common warts present will receive YCANTH (VP-102/TO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0/+ 8 days).
If participants still have warts present after 4 additional treatments of YCANTH (VP-102/TO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site:
vesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102/TO-208). Participants may receive treatment until all treatable common warts are clear, up to a maximum of 4 treatment sessions, or until Day 357, whichever occurs first.
Treatment:
For participants with warts present at the time of study entry, the first treatment application may occur on the same day as transition from the parent study. All required parent study assessments must be complete, including the final evaluation of response to treatment (ERT; as defined in Assessments and procedures).
In addition, eligibility for participation in the LTFU study must have been determined, and informed consent/assent for participation in this LTFU study obtained. YCANTH (VP-102/TO-208) will be applied by the Investigator or qualified member of the research team to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. After YCANTH (VP-102/TO- 208) is applied, warts are to be covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and should be removed 24 hours after application of study drug and just before a 24-hour ERT. Before application of study drug, wart paring, if necessary, will be completed with a sharp surgical instrument (eg, scalpel or flexible medical blade) to remove any adherent thick scale from a treatable common wart. Wart paring is required to be performed at any treatment visit when adherent thick scale is present, and the Investigator feels paring can be safely performed. Paring should be conducted by a trained practitioner and in compliance with any local regulations and should be discontinued if it results in punctate bleeding or significant pain. Not all treatable common warts may require paring. If adherent scale is not present, study drug can be applied without paring. The assessment for complete clearance may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated, and the visit will be documented as an Unscheduled Visit. The timing of the next treatment visit will be determined by resolution of the LSRs. The research team will be in contact with the Participant until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. All treatable common warts that are not completely clear should undergo treatment with study drug. Study duration from Days 84, 105, or 147 of the parent study (COVE-2 or COVE-3) through the final EOS visit of this LTFU study (Day 378) is approximately 294 days.

开始日期2026-03-11

申办/合作机构

Verrica Pharmaceuticals, Inc.

[+5]

100 项与斑蝥素相关的临床结果

登录后查看更多信息

100 项与斑蝥素相关的转化医学

登录后查看更多信息

100 项与斑蝥素相关的专利（医药）

登录后查看更多信息

1,112

项与斑蝥素相关的文献（医药）

2026-12-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The Pt(IV) complexes of norcantharidin axial-modulated by carboxylic acid ligand: Synthesis, characterization, in vitro/in vivo anticancer efficacy and hypoxic activity

Article

作者: Liu, Yuan ; Bi, Xue-Bin ; Li, Dong-Mei ; Liang, Hong ; Storr, Tim ; Liu, Yan-Cheng ; Wen, Chang-Chun ; Huang, Yue ; Liu, Rui-Xue ; Ding, Tong-Yan ; Luo, Sha-Sha

Norcantharidin (NCTD), a semi-synthetic derivative of cantharidin from the animal-derived traditional Chinese medicine Cantharides, was selected as a potential functional anticancer ligand. Then three new Pt(IV) complexes (Pt-NCTD-bu, Pt-NCTD-pe, Pt-NCTD-he) were designed as a homologous series to evaluate how increasing axial chain length affects lipophilicity and anticancer efficacy. The axial carboxylate ligands were employed to modulate lipophilicity and coordination stability. These complexes exhibited stronger cytotoxicity against the most sensitive A2780 cells than cisplatin, with the order of potency following he > pe > bu, correlating with increasing lipophilicity and cellular uptake. All three complexes also effectively suppressed colony formation. They also overcame cisplatin resistance in A2780/CDDP cells. Mechanistically, they could release active Pt(II) and NCTD via GSH-mediated reduction, inducing ROS accumulation, mitochondrial dysfunction, DNA damage and cell apoptosis. Especially, under intracellular hypoxia condition, Pt-NCTD-he showed the highest oxygen-independent cytotoxicity. In vivo, Pt-NCTD-he (20 mg/kg) more effectively suppressed tumor growth in A2780 xenografts than cisplatin, with a 70.0% inhibition rate. Pt-NCTD-he was found to mainly distribute in the liver, indicating that a higher lipophilicity is conducive to better anticancer activity. Pt-NCTD-he also showed satisfactory pharmacokinetic properties, with a longer elimination half-life (1.3 h) than cisplatin (ca. 0.5 h). This work highlights the rational design of Pt(IV) complexes by integrating natural medicinal ingredients, providing a promising strategy for the new generation of Pt(IV)-based complexes as anticancer prodrugs.

2026-11-01·BURNS

Identification and validation of mitotic catastrophe–associated biomarkers for keloid

Article

作者: Kong, Zhen ; Yan, Fei ; Yuan, Wei-Wei ; Yu, Li ; Sun, Hui ; Liu, Li-Ping

PURPOSE:

Exploring the role of mitotic catastrophe-related genes (MCRGs) in the development of keloid, a benign skin disorder.

METHODS:

Differentially expressed genes (DEGs) between keloid and normal tissues were identified. Candidate genes at the intersection of DEGs and MCRGs were selected. Protein-protein interaction network, machine learning, and expression analyses allowed the identification of keloid-associated biomarkers. Nomogram construction, Gene Set Enrichment Analysis (GSEA), and immune cell infiltration, molecular regulatory network, drug prediction, and molecular docking analyses were conducted. Biomarker expression in clinical samples was then experimentally validated.

PRINCIPAL RESULTS:

Protein phosphatase 1 catalytic subunit alpha (PPP1CA) and nuclear distribution C (NUDC) were determined to be the biomarkers, and the nomogram demonstrated their effective predictive potential for keloid. A higher expression of PPP1CA and NUDC was associated with the GSEA gene sets NEUTROPHIL_DEGRANULATION/WP_TRANSLATION_FACTORS and GLUCONEOGENESIS/GLUCOSE_METABOLIC_PROCESS, respectively. Analysis of immune cell infiltration into keloid tissue revealed high correlation between the abundance of specific T-cell populations and the biomarkers. The microRNAs hsa-miR-31315b/hsa-miR-6856-5p and hsa-miR-4743-3p/hsa-miR-8089 were found to be associated with PPP1CA and NUDC, respectively. Furthermore, six transcription factors, including specificity protein 1 and erythroblast transformation specific like-1, were identified to regulate the two biomarkers. PPP1CA exhibited favorable binding affinity toward cantharidin, and NUDC exhibited favorable binding affinity toward latamoxef. These findings were preliminarily validated via in vitro expression analysis.

MAJOR CONCLUSION:

The two MCRGs PPP1CA and NUDC were identified as promising biomarkers with potential roles in keloid pathogenesis and as therapeutic targets.

2026-10-01·BIOORGANIC CHEMISTRY

Cantharidin analogue NCTD-01 inhibits AOM/DSS-induced orthotopic colorectal carcinogenesis in mice by suppressing inflammation-driven tumorigenesis

Article

作者: Wang, Yinyue ; Zeng, Guangzhi ; Shi, Hongtao ; Zhao, Yu-Qiang ; Zhang, Ruyi ; Hu, Xueyao ; Fan, Baomin ; Xu, Yangjiao ; Yu, Nairong

Although cantharidin (CTD) exhibits significant clinical efficacy against various cancers, its clinical utility is severely hampered by profound systemic toxicity. Thus, structural modification of CTD to obtain analogues with potent anticancer activity and lower toxicity is essential for advancing CTD-based therapeutics. Building on our previous synthesis of a series of C-5 alkynyl-substituted CTD analogues with potent anti-inflammatory properties, this study investigates the anticancer potential of a new analogue NCTD-01 demonstrated a favorable safety profile in mice, with the maximum tolerated dose (MTD) for oral administration exceeding 1852 mg/kg. In addition to exhibiting potent in vitro and in vivo anti-inflammatory activities comparable to its analogues, NCTD-01 displayed cytotoxicity against colon cancer cell lines and exhibited therapeutic efficacy in an azoxymethane/dextran sulfate sodium-induced orthotopic mouse model of colorectal cancer. Molecular analyses revealed that NCTD-01 reduced Ki-67 expression, suppressed the mRNA levels of pro-inflammatory and immunosuppressive mediators (IL-1β, COX-2, IL-6, IL-10, and TGF-β) in colonic tumor tissues, and decreased serum levels of TNF-α and IL-1β. Furthermore, NCTD-01 treatment led to reduced expression of Foxp3, CD25, PD-1, and PD-L1, alongside enhanced CD8 and GITR expression in colorectal tissues, suggesting an effective modulation of tumor-associated immune responses. This study suggests that NCTD-01, a new C-5 alkynyl-substituted CTD analogue, may help alleviate the inflammation-to-cancer transition through tumor-associated immune modulation while maintaining a favorable safety profile, pointing to its potential as a candidate for anticancer drug discovery.

161

项与斑蝥素相关的新闻（医药）

2026-10-22

·BioSpace

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and advancement of the Company’s global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1’27 – WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it has achieved the pre-defined revenue, growth and operational milestones required to increase the maximum commitment amount under its credit facility with an entity controlled by Paul B. Manning, Chairman and Chief Executive Officer of PBM Capital and Chairman of Verrica's Board of Directors. As a result of the achievement of these milestones, the full $27.5 million of non-dilutive capital under the facility is now available to Verrica, with the first $12.5 million having been funded in September. "Verrica’s achievement of these milestones resulted directly from the momentum our team has built with YCANTH," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "We committed to clear revenue, growth and operational goals when we closed this facility in August, and we delivered on them. Importantly, the capital now available to Verrica by this facility allows us to complete our two pivotal studies in the common warts program, with readouts from the studies expected in the first quarter and in mid-2027, respectively. Under the facility, we have no obligation to make scheduled principal or interest cash payments during the term of the facility, and the favorable covenant package allows us to fully utilize our cash to support our growth. On behalf of all of us at Verrica, I would like to again thank Paul Manning for his confidence in our progress and for providing this highly flexible funding to support our programs." "Verrica's execution over the past several months reinforces my confidence in the team and in YCANTH," said Paul B. Manning, Chairman of Verrica's Board of Directors. "I am pleased to continue supporting the Company as it builds on this progress." Terms of the Credit Agreement Under the terms of credit agreement, Verrica may borrow up to $27.5 million from time to time, at its option. Borrowings under the facility will bear interest at the one-month secured overnight financing rate (SOFR) plus 8.00% per annum, subject to a SOFR floor of 4.50%. All interest under the facility will be payable in kind, subject to the absence of any event of default under the credit agreement (which results in interest being payable in cash and increased during the pendency of such event of default, unless otherwise elected by the lender). The term loans will mature on December 31, 2030. The credit agreement also requires mandatory prepayments with the proceeds of certain transactions and events, and quarterly payments if positive operating cash flow exceeds a specified amount. The credit facility is secured by substantially all of the assets of Verrica and certain subsidiaries. About YCANTH® (VP-102) YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay as little as $0 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information. YCANTH is also approved for the treatment of molluscum contagiosum in Japan and is being studied in a global phase 3 program in the US and Japan for the treatment of common warts. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrica’s ability to borrow funds under the credit facility, the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, the timing of readouts from the Phase 3 common warts program and Verrica’s cash runway. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

2026-10-11

·Complex TCM

中医肿瘤论文推送（2026.10.10）

每周论文更新 · 2026.10.10中医肿瘤论文本期 9 篇 · 发表于 2026.10.05–2026.10.10 基础与机制 3观察性研究 2综述 2系统综述与Meta分析 1混合方法研究 1 每篇先看「结论」，轻触条目展开完整中文摘要；条目下方 DOI 或原文来源可长按复制检索。 01基础与机制花椒毒酚抗胃癌的分子机制：整合网络药理学、计算机模拟和实验验证的综合研究Animal models and experimentalmedicine2026-10-09 · JIF 待核验中文摘要背景：胃癌（GC）是全球范围内常见的消化系统恶性肿瘤。花椒毒酚（Xan）是一种从欧当归（Angelicaarchangelica）等中药中提取的天然化合物，已表现出抗肿瘤特性。然而，其对 GC 的具体作用尚未见报道。方法：通过整合加权基因共表达网络分析（WGCNA）与网络药理学，鉴定了 Xan治疗 GC 的核心靶点。进行了分子对接和分子动力学（MD）模拟，以分析核心靶点与 Xan 之间的相互作用。利用细胞实验和异种移植肿瘤模型检测了 Xan 对 GC 细胞增殖、细胞周期、凋亡、迁移和侵袭的影响。在 Xan 干预后，对肿瘤和肝脏组织的病理组织学改变进行了评估。采用Western blot 和逆转录定量聚合酶链反应（RT-qPCR）分析核心靶点的表达，并阐明 Xan 抗 GC 的分子机制。结果：共鉴定出 6 个与 GC 高度相关的核心基因（MMP12、KDR、CCND1、PDGFRB、PLAU 和 PLK1）。分子对接和 MD 模拟显示 Xan 与核心基因之间存在显著的结合亲和力。实验表明，Xan 抑制了增殖、细胞周期、迁移和侵袭，同时促进了凋亡。Xan 能够减轻小鼠皮下肿瘤引起的肝损伤。此外，在 GC 细胞中，Xan 上调了MMP12 的表达，并下调了 KDR、CCND1、PDGFRB、PLAU 和 PLK1的表达。结论：Xan 有望作为一种 GC 治疗药物，其通过调节 MMP12、KDR、CCND1、PDGFRB、PLAU 和 PLK1 的表达，从而抑制增殖、细胞周期、迁移和侵袭，同时增强凋亡并减轻肝损伤。原文题名：Molecular mechanism ofXanthotoxol against gastric cancer: Acomprehensive study integratingnetwork pharmacology, computersimulations, and experimentalvalidation作者：Yang, Yi；Du, Yu-Hua；Song,Chuang 等 11 位作者检索来源：PubMed;Crossref文献标识：PubMed:42855855;Crossref:10.1002/ame2.70234关键词：MD simulations；Xanthotoxol；experimental validation；gastriccancer；molecular docking 花椒毒酚抗胃癌的分子机制：整合网络药理学、计算机模拟和实验验证的综合研究Animal models and experimentalmedicine2026-10-09 · JIF 待核验结论Xan 有望作为一种 GC 治疗药物，其通过调节 MMP12、KDR、CCND1、PDGFRB、PLAU 和 PLK1 的表达，从而抑制增殖…轻触展开完整中文摘要 ↓ 原文 DOI · 10.1002/ame2.70234 02基础与机制参苓启膈颗粒通过调控 DCN-TGF-β/Smad 信号轴抑制 TE-1 异种移植瘤和细胞模型中食管鳞状细胞癌的进展PloS one2026-10-06 · JIF 2025 2.8中文摘要参苓启膈颗粒（SLQG）源自《医学心悟》所载清代方剂启膈散，在中国临床实践中已被用作食管鳞状细胞癌（ESCC）的辅助中药制剂，但其分子基础尚不明确。本研究利用 TE-1 异种移植小鼠和含 SLQG 血清处理的 TE-1 细胞探讨了 SLQG 的抗肿瘤作用和机制。整合转录组测序、网络药理学、分子对接、分子动力学模拟和公共数据库分析，以确定候选机制的优先级。进行了组织学、分子、细胞以及 siRNA介导的核心蛋白聚糖（DCN）敲低实验以进行验证。SLQG（尤其是中剂量）抑制了异种移植肿瘤的生长并增加了DCN 的表达。转录组学分析突显了转化生长因子-β（TGF-β）/Smad 通路。计算机模拟分析表明，几种源自 SLQG 的化合物，尤其是熊果酸，可能与 DCN相关的调控有关。公共数据库分析表明，食管癌肿瘤样本中的 DCN 表达低于正常样本，且与病理分期相关。在体内和体外，SLQG 增加了 DCN 的表达，降低了 Smad2/3 磷酸化，促进了促凋亡信号传导，并诱导了 G0/G1期阻滞；这些效应被 DCN 敲低所减弱。这些发现表明，SLQG 抑制了 TE-1异种移植和细胞模型中的 ESCC 进展，这可能是通过调控 DCN 相关的 TGF-β/Smad 信号轴实现的。原文题名：Shenling Qige Granules inhibitesophageal squamous cell carcinomaprogression in TE-1 xenograft and cell-based models by modulating the DCN-TGF-β/Smad signaling axis作者：Liu, Zihui；Gu, Yiting；Fan,Huanfang 等 9 位作者期刊指标来源：Journal Citation Reports，2026 年发布（2025 年数据）检索来源：PubMed;OpenAlex;Crossref文献标识：PubMed:42837419;OpenAlex:W7220659296;Crossref:10.1371/journal.pone.0359405关键词：esophageal squamous cellcarcinoma；decorin；TGF-β/Smadsignaling；ursolic acid；traditionalChinese medicine；Smad2/3phosphorylation；apoptosis；G0/G1cell cycle arrest；anticancermechanism 参苓启膈颗粒通过调控 DCN-TGF-β/Smad 信号轴抑制 TE-1 异种移植瘤和细胞模型中食管鳞状细胞癌的进展PloS one2026-10-06 · JIF 2025 2.8摘要要点这些发现表明，SLQG 抑制了 TE-1异种移植和细胞模型中的 ESCC 进展，这可能是通过调控 DCN 相关的 TGF-β/Smad 信…轻触展开完整中文摘要 ↓ 原文 DOI · 10.1371/journal.pone.0359405 03基础与机制质谱分子网络结合网络药理学揭示菊苣酸为蒲公英（Taraxacum mongolicumHand.-Mazz.）中潜在的 ROS相关抗肿瘤成分Journal of ethnopharmacology2026-10-05 · JIF 2025 6.8中文摘要民族药理学相关性：三阴性乳腺癌（TNBC）是侵袭性最强的亚型，导致了女性癌症患者的主要死亡。由于其高度异质性，目前仍缺乏针对 TNBC 的有效疗法。蒲公英（Taraxacummongolicum Hand.-Mazz.，TM）作为中药具有悠久历史，具有清热、解毒和散结的功效。尽管多项研究已证实 TM 具有良好的抗TNBC 潜力，但其候选生物活性成分和潜在作用机制尚未完全阐明。研究目的：本研究旨在通过质谱分子网络、网络药理学预测和实验验证相结合的策略，揭示 TM 抗 TNBC 的主要活性成分及其潜在机制。材料与方法：在正负离子模式下，采用 UPLC-Q-Exactive Orbitrap MS 对 TM 进行了分析。应用基于特征的分子网络方法全面鉴定 TM 提取物中的潜在酚酸类和黄酮类化合物，以及给药后大鼠血浆中的吸收成分。基于这些吸收成分进行了网络药理学分析，以预测 TM 提取物的机制和潜在活性成分。随后在体内和体外评估了 TM 提取物及潜在活性成分抗 TNBC 的疗效。结果：结果表明，在 TM 提取物中共鉴定出31 种酚酸和 17 种黄酮类化合物。并将 22 种吸收成分用于网络药理学分析，提示其与 ROS 相关通路高度相关。低剂量的 TM 提取物显著抑制了TNBC 细胞衍生异种移植小鼠的肿瘤生长，同时提高了 ROS 水平和细胞凋亡。然而，与模型组相比，较高剂量的 TM提取物未显示出显著变化。在经菊苣酸处理的 TNBC 细胞衍生异种移植小鼠中也观察到了类似现象。结论：本研究表明，菊苣酸是 TM 提取物中抗TNBC 的潜在成分，其疗效表现出非单调的剂量-反应特征，挑战了更高剂量总是产生更优治疗效果的普遍假设。原文题名：Mass spectrometrymolecular networking coupled withnetwork pharmacology reveals cichoricacid as the potential ROS-associatedantitumor constituent in Taraxacummongolicum Hand.-Mazz作者：Liu, Feng-Jie；Xu, Li；Yang, Ke-Ke 等 6 位作者期刊指标来源：Journal Citation Reports，2026 年发布（2025 年数据）检索来源：PubMed;Crossref文献标识：PubMed:42833367;Crossref:10.1016/j.jep.2026.122473关键词：Feature-based molecularnetworking；Network pharmacology；ROS；Taraxacum mongolicum；Triplenegative breast cancer 质谱分子网络结合网络药理学揭示菊苣酸为蒲公英（Taraxacum mongolicumHand.-Mazz.）中潜在的 ROS相关抗肿瘤成分Journal of ethnopharmacology2026-10-05 · JIF 2025 6.8结论本研究表明，菊苣酸是 TM 提取物中抗TNBC 的潜在成分，其疗效表现出非单调的剂量-反应特征，挑战了更高剂量总是产生更…轻触展开完整中文摘要 ↓ 原文 DOI · 10.1016/j.jep.2026.122473 04观察性研究中医药联合常规疗法对转移性前列腺癌患者生存的影响：一项回顾性观察性队列研究Frontiers in Oncology2026-10-05 · JIF 2025 3.4中文摘要背景：在中国，中医药（TCM）已被纳入晚期前列腺癌的长期整合管理中，但将治疗持续时间与生存期联系起来的证据仍然有限。由于治疗持续时间在随访期间累积，根据最终记录的治疗持续时间对患者进行分类可能会错误分配阈值前的观察时间，并导致生存比较产生偏倚。方法：我们在一个由 242 例确诊时即为转移性前列腺腺癌且自确诊起接受持续TCM 治疗的患者组成的单中心回顾性队列中，评估了累计持续 TCM 治疗超过 6 个月与全因死亡率之间的关联。随访持续至 2024 年 5 月 1 日。在多变量 Cox 回归中，将治疗超过 6个月作为时变暴露进行建模，并针对备选阈值、疾病严重程度调整、具影响力观测值和失访进行了敏感性分析。结果：随访期间共发生 147 例死亡。中位总生存期为 53.0 个月（95% 置信区间 [CI]，44.0-61.0），3 年和 5 年生存率分别为 64.0% 和 43.4%。累计持续 TCM 治疗超过 6 个月与较低的全因死亡平均风险相关（调整后危险比 [HR]，0.269；95% CI，0.186-0.389；P < 0.001）。该关联随时间减弱：1 年、2 年、3 年和 5 年时的调整后 HR 分别为 0.098、0.192、0.286 和 0.471。敏感性分析得出了相同方向的估计值。结论：这些发现明确了 TCM 使用者中疗程与生存期的关联，并支持利用详细的纵向治疗记录开展前瞻性、多中心评估。原文题名：Impact of traditionalChinese medicine combined withconventional therapies on the survivalof patients with metastatic prostatecancer: a retrospective observationalcohort study作者：Jianfu Zhou；Shuyang Yang；Hetao Chen 等 10 位作者期刊指标来源：Journal Citation Reports，2026 年发布（2025 年数据）检索来源：OpenAlex;Crossref文献标识：OpenAlex:W7219851339;Crossref:10.3389/fonc.2026.1948429关键词：traditional Chinese medicine；metastatic prostate cancer；all-causemortality；overall survival；treatment duration；integrativeoncology；survivorship bias；time-varying exposure 中医药联合常规疗法对转移性前列腺癌患者生存的影响：一项回顾性观察性队列研究Frontiers in Oncology2026-10-05 · JIF 2025 3.4结论这些发现明确了 TCM 使用者中疗程与生存期的关联，并支持利用详细的纵向治疗记录开展前瞻性、多中心评估。轻触展开完整中文摘要 ↓ 原文 DOI · 10.3389/fonc.2026.1948429 05综述仙鹤草活性成分干预结直肠癌机制的研究进展Theoretical and Natural Science2026-10-08 · JIF 待核验中文摘要结直肠癌（CRC）是全球最常见的消化系统恶性肿瘤之一，遗传易感性、慢性炎症和生活习惯均被认为在其发生发展中起促进作用。目前手术、化疗和靶向治疗仍是临床治疗的主要支柱，然而，肿瘤侵袭与转移、多药耐药以及放化疗的不良反应仍是影响整体治疗疗效的主要障碍。仙鹤草（Agrimonia pilosa，Xianhecao）作为一种广泛应用的中药，含有包括黄酮类、鞣质和多酚在内的多种生物活性成分。现代药理学证据表明，这些活性化合物能够抑制CRC细胞的增殖、侵袭和转移，逆转多药耐药，并调控糖酵解、自噬以及JAK/STAT和JNK/AKT等多条信号通路。本综述总结了仙鹤草（A. pilosa）的化学物质基础，探讨了其抗CRC活性的分子机制，并综述了现有的临床观察性研究。本文还指出了当前研究的不足并提出了未来的研究方向，旨在为仙鹤草（A. pilosa）抗CRC的实验与临床研究提供参考。原文题名：Research Progress on theMechanisms of Active Componentsfrom Agrimonia pilosa in InterveningColorectal Cancer作者：Hongli He检索来源：OpenAlex;Crossref文献标识：OpenAlex:W7220961018;Crossref:10.54254/2753-8818/2026.37505关键词：Agrimonia pilosa；colorectalcancer；traditional Chinese medicine；flavonoids；tannins；polyphenols；multidrug resistance；tumor invasionand metastasis；glycolysis；autophagy；JAK/STAT signaling；anticancermechanism 仙鹤草活性成分干预结直肠癌机制的研究进展Theoretical and Natural Science2026-10-08 · JIF 待核验摘要要点本文还指出了当前研究的不足并提出了未来的研究方向，旨在为仙鹤草（A.pilosa）抗CRC的实验与临床研究提供参考。轻触展开完整中文摘要 ↓ 原文 DOI · 10.54254/2753-8818/2026.37505 06综述从古代医学思想到现代卫生系统：“以毒攻毒”原则在癌症治疗中的现代转化Theoretical and Natural Science2026-10-08 · JIF 待核验中文摘要“以毒攻毒”是中医学治疗疑难杂症的重要原则。它利用有毒药物的治疗作用，为现代抗肿瘤药物研发提供了独特的策略。本综述探讨了“以毒攻毒”的理论基础与现代发展。讨论了三种代表性有毒药物：三氧化二砷（ATO）、斑蝥素与去甲斑蝥素，以及蟾毒灵（bufalin）。系统综述了它们的药理来源、抗肿瘤分子机制、临床应用及减毒途径。研究表明，ATO通过靶向PML-RARα融合蛋白促进急性早幼粒细胞白血病细胞分化和凋亡；斑蝥素及其结构修饰产物主要通过多靶点调控抑制肿瘤细胞增殖并诱导凋亡；而蟾毒灵（bufalin）则通过影响PI3K/Akt和MAPK等多条信号通路表现出广泛的抗肿瘤活性。然而，目前的研究仍主要基于基础和临床前证据，且仍缺乏治疗窗、毒性评价和高质量的临床证据。未来的研究应加强在精准给药、毒性监测、药物递送和随机对照试验方面的研究，以推动传统理论向标准化、精准化和国际化的现代癌症治疗模式转化。原文题名：From Ancient MedicalThought to Modern Health Systems:The Modern Translation of the "Fighting Poison with Poison" Principlein Cancer Therapy作者：Hailu Wang检索来源：OpenAlex;Crossref文献标识：OpenAlex:W7221012641;Crossref:10.54254/2753-8818/2026.hz37472关键词：traditional Chinese medicine；arsenic trioxide；cantharidin；norcantharidin；bufalin；anticancerdrug development；acutepromyelocytic leukemia；PML-RARαfusion protein；apoptosis；PI3K/Aktsignaling；MAPK signaling 从古代医学思想到现代卫生系统：“以毒攻毒”原则在癌症治疗中的现代转化Theoretical and Natural Science2026-10-08 · JIF 待核验摘要要点未来的研究应加强在精准给药、毒性监测、药物递送和随机对照试验方面的研究，以推动传统理论向标准化、精准化和国际化的现…轻触展开完整中文摘要 ↓ 原文 DOI · 10.54254/2753-8818/2026.hz37472 07观察性研究中西医结合疗法治疗转移性结直肠癌的临床疗效World Journal of Clinical Oncology2026-10-08 · JIF 待核验中文摘要背景：转移性结直肠癌（mCRC）的全身治疗受到毒性、耐药性以及患者耐受性各异的限制。中西医结合疗法在中国得到广泛应用，但其在真实世界环境中与生存期的关联需要谨慎评估。目的：利用基于目标试验模拟的观察性研究设计，评估中西医结合疗法与mCRC患者生存期之间的关联。方法：这项回顾性多中心队列纳入了2017年1月1日至2026年1月1日期间接受治疗的mCRC患者。目标试验模拟的各个组成部分均经过预先指定。根据观察到的口服中药使用持续时间对患者进行分类（≥ 3个月 vs < 3个月）。主要结局为总生存期（OS），次要结局为癌症特异性生存期。采用稳定逆概率加权来平衡已测量的基线协变量。随后使用加权Cox模型评估生存关联。由于分组是由基线后的治疗持续时间定义的，因此估计值被解释为关联而非因果效应。结果：在筛选的649例患者中，627例符合条件：490例接受口服中药治疗≥3个月，137例接受口服中药治疗< 3个月。加权后，≥ 3个月组中的259例患者和< 3个月组中的111例患者纳入了分析。所有报告的标准化均数差均<0.1。≥ 3个月组的中位OS为37.5个月，< 3个月组为19.5个月。< 3个月组观察到更高的癌症特异性死亡风险[危险比（HR）= 6.327,95%CI: 3.692-10.844]和全因死亡风险（HR = 14.954, 95%CI: 9.054-24.701; P < 0.001）。不应将这种异常偏大的HR解释为因果治疗效应。其数值大小可能受到了基于持续时间的分组、残余混杂以及模型设定的影响。结论：在这一多中心真实世界队列中，作为中西医结合疗法的一部分，口服中药使用≥ 3个月与mCRC患者更长的OS和癌症特异性生存期相关。在确定因果效应或临床获益之前，需要开展采用界标和时变暴露分析的前瞻性研究。原文题名：Clinical efficacy ofintegrated Chinese-Western medicinetherapy for metastatic colorectalcancer作者：Rui Li；Yu-ying XU；Beibei Wu 等9 位作者检索来源：OpenAlex;Crossref文献标识：OpenAlex:W7220941150;Crossref:10.5306/wjco.124301关键词：metastatic colorectal cancer；traditional Chinese medicine；combination therapy；clinical efficacy 中西医结合疗法治疗转移性结直肠癌的临床疗效World Journal of Clinical Oncology2026-10-08 · JIF 待核验结论在这一多中心真实世界队列中，作为中西医结合疗法的一部分，口服中药使用≥ 3个月与mCRC患者更长的OS和癌症特异性生存…轻触展开完整中文摘要 ↓ 原文 DOI · 10.5306/wjco.124301 08系统综述与Meta分析针刺治疗结直肠癌术后胃肠功能障碍的系统评价与Meta分析World Journal of GastrointestinalOncology2026-10-08 · JIF 待核验中文摘要背景：胃肠功能障碍在结直肠癌术后常见，且常常妨碍康复。目的：探讨针刺是否有助于促进结直肠癌术后患者胃肠功能恢复及其是否安全。方法：我们检索了截至2026年7月20日的PubMed、EMBASE、Web ofScience和CENTRAL数据库中比较针刺联合常规护理与单纯常规护理或假针刺的随机对照试验。两位评价员独立进行筛选、数据提取和偏倚风险评估（修订版Cochrane随机试验偏倚风险评估工具）。主要结局为首次排气时间和首次排便时间。使用I 2统计量检验异质性，并根据异质性采用随机或固定效应模型。结果：共纳入8项随机对照试验，涉及1365例患者。针刺显著缩短了首次排气时间[均数差（MD）= -8.72 小时, 95%CI:-14.01 to -3.44,I 2 = 88%]和首次排便时间（MD = -13.32小时, 95%CI -20.12 to -6.52,I 2 = 80%）。住院时间：无显著差异（MD = -10.63小时, 95%CI: -33.99 to 12.74, I 2= 73%）。亚组分析表明，针刺对胃肠功能恢复的作用在不同针刺方式间存在差异，而敏感性分析提示异质性部分由研究设计和对照类型的差异所致。未发生严重不良事件。证据的总体质量为中等。结论：针刺可加速结直肠癌术后胃肠功能恢复且似乎是安全的，但其对住院时间的影响仍不确定。尚需进一步开展设计良好的研究。原文题名：Systematic review and meta-analysis of acupuncture forpostoperative gastrointestinaldysfunction after colorectal cancersurgery作者：Xinrui Zhang；Pei Wang；ZhengWang 等 4 位作者检索来源：OpenAlex;Crossref文献标识：OpenAlex:W7221032881;Crossref:10.4251/wjgo.123593关键词：acupuncture；postoperativegastrointestinal dysfunction；colorectal cancer surgery；postoperative ileus；bowel functionrecovery 针刺治疗结直肠癌术后胃肠功能障碍的系统评价与Meta分析World Journal of GastrointestinalOncology2026-10-08 · JIF 待核验结论针刺可加速结直肠癌术后胃肠功能恢复且似乎是安全的，但其对住院时间的影响仍不确定。尚需进一步开展设计良好的研究。轻触展开完整中文摘要 ↓ 原文 DOI · 10.4251/wjgo.123593 09混合方法研究门诊照护中跨专业整合肿瘤学咨询项目的就诊原因和推荐干预措施：对1,693封咨询信的混合方法分析Frontiers in Medicine2026-10-07 · JIF 2025 3.6中文摘要引言：补充与整合医疗（CIH）方法在肿瘤照护中发挥着越来越重要的作用，涉及广泛的医疗专业人员和治疗方法。尽管患者对CIH的需求以及各个干预措施的证据基础已大幅增长，但用于有效且安全使用CIH的结构化咨询服务的实施仍然有限。为填补这一空白，在德国的4家综合癌症中心（CCC）开展了一项对照、多中心实施研究，以建立针对CIH的门诊、跨专业、循证咨询服务（CCC-Integrativ）。这项混合方法研究调查了这些咨询过程中的具体就诊原因（RfE）和推荐的干预措施。方法：纳入CCC-Integrativ研究的患者在3个月内接受了3次CIH咨询，其中第一次咨询由接受过专门培训的医生和护士共同进行。每次咨询后，均准备了一份咨询信，总结患者的主要RfE和建议。所有咨询信均采用定性内容分析法进行分析，随后对结果进行了定量分析。结果：共分析了来自603名肿瘤患者的1,693封咨询信。最常见的就诊原因包括全身虚弱和疲劳（56%）、化疗引起的周围神经病变（40%）、睡眠障碍（37%）和全身疼痛（36%）。几乎所有患者都接受了关于生活方式改变的咨询，包括营养（95%）、身体活动（93%）和压力管理（81%）。此外，平均每位患者获推荐15项具体的CIH干预措施，涵盖自然疗法护理干预（97%）、草药和茶剂（79%）、穴位按压（79%）以及基于正念的运动疗法（44%）。讨论：肿瘤学中关于CIH的跨专业门诊咨询涉及广泛的患者RfE，提供生活方式改变方面的指导，并提供具体的个体化CIH干预措施以帮助患者应对令人负担沉重的症状。这些发现表明，跨专业整合咨询服务通过提供针对个体需求量身定制的整体方法，可以在门诊肿瘤照护中发挥关键作用。此外，结构化整合肿瘤学咨询在门诊照护环境中可发挥有价值的导向作用。原文题名：Reasons for encounter andrecommended interventions in aninterprofessional integrative oncologycounseling program in outpatient care:a mixed-methods analysis of 1,693consultation letters作者：Andreas Schmitt；Regina Stolz；Holger Mauch 等 9 位作者期刊指标来源：Journal Citation Reports，2026 年发布（2025 年数据）检索来源：OpenAlex;Crossref文献标识：OpenAlex:W7220842491;Crossref:10.3389/fmed.2026.1907654关键词：integrative oncology；outpatient oncology；interprofessionalcare；nurse-physician collaboration；reasons for encounter；lifestylemodification；fatigue；chemotherapy-induced peripheral neuropathy；sleepdisorders；pain；herbal medicine；acupressure；symptom management 门诊照护中跨专业整合肿瘤学咨询项目的就诊原因和推荐干预措施：对1,693封咨询信的混合方法分析Frontiers in Medicine2026-10-07 · JIF 2025 3.6摘要要点此外，结构化整合肿瘤学咨询在门诊照护环境中可发挥有价值的导向作用。轻触展开完整中文摘要 ↓ 原文 DOI · 10.3389/fmed.2026.1907654 阅读说明本期于 2026 年 10 月 10 日检索，按日期、文献标识与主题内容筛选。中文摘要由机器翻译并经文本核对；「结论」摘自摘要的结论部分；试验方案取方法部分首句作「研究设计」；其余取摘要末句作「摘要要点」。均为原句摘录，重要结论请回到原文核验。本篇 4 条记录的 2025 JIF 已核对，5 条待核验；待核验不表示零或已确认没有 JIF。JIF 是期刊层面指标，不代表单篇论文质量。研究类型为辅助标注。本文不构成诊断、治疗或用药建议。

2026-09-30

·BioSpace

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of YCANTH® (VP-102) and an encore presentation of data from a Phase 2 trial of VP-315. Verrica will present at the Fall Clinical Dermatology Conference (October 8–11, Wynn Las Vegas, Las Vegas, NV) and at the 2026 PeDRA Annual Conference (October 15–17, Alexandria, VA). "We remain highly encouraged by the continued generation of clinical evidence supporting our dermatology portfolio," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "These new pooled data from the CAMP-1 and CAMP-2 Phase 3 trials reinforce VP-102’s pro the new standard of care for molluscum contagiosum, showing that patients may achieve complete clearance of their molluscum lesions approximately four times faster than with vehicle, regardless of how long patients have had the disease. In addition, three times as many patients treated with YCANTH achieved complete clearance versus vehicle at each time point measured during the two trials, which reflects the consistent and durable treatment effects of YCANTH. We believe this new analysis provides physicians further confidence to treat patients with YCANTH as soon as a diagnosis is made, rather than defaulting to a ‘watch and wait’ approach typically employed by healthcare professionals before an FDA-approved option existed for patients." "We continue to analyze the YCANTH data to help us better understand its ability to reduce the impact of disease upon patients, and accelerate their return to normal activities," added Noah L. Rosenberg, M.D., Chief Medical Officer of Verrica. "This data, demonstrating more rapid complete clearance with YCANTH, independent of disease duration, gives clinicians a clear, data-driven rationale for early intervention rather than watchful waiting." About the Posters: VP-102 Achieved Complete Clearance Approximately 4 Times Faster Than Vehicle, Regardless of Disease Duration The Company will present results from a post-hoc pooled analysis of two completed Phase 3 trials of YCANTH for the treatment of molluscum contagiosum (molluscum), evaluating time to first complete clearance and the impact of disease duration on treatment response. Key new findings include: Subjects treated with VP-102 achieved complete clearance at an approximately 4-fold faster rate than vehicle (HR=4.06; 95% CI, 2.94–5.74), with treatment-effect estimates ranging from 4.05 to 4.19 across sensitivity analyses. Kaplan-Meier cumulative complete clearance by Day 84 was 60.1% with VP-102 versus 19.9% with vehicle. Potential Abscopal Effect of VP-315 in Untreated Basal Cell Carcinoma Tumors Verrica will present an encore poster, previously presented at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, describing an exploratory analysis of potential abscopal-like effects of VP-315, the Company's investigational oncolytic peptide immunotherapy, in patients with basal cell carcinoma (BCC). The analysis examined untreated, non-target lesions (NTLs) in subjects from Part 2 of a Phase 2 multicenter study following intratumoral treatment with VP-315 of separate target lesions. Presentation Details 2026 Fall Clinical Dermatology Conference | October 8–11, 2026 | Wynn Las Vegas, Las Vegas, NV Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7 Time of Poster Session: Friday, October 9 th , 7:00 am - 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT Saturday, October 10 th , 7:30 am - 12:30 pm PDT (Exhibits and Poster Gallery Open) Sunday, October 11 th , 7:00 am – 1:00 pm PDT (Poster Gallery Open) Poster: VP-315 Demonstrates a Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors (Encore) Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7 Time of Poster Session: Friday, October 9 th , 7:00 am - 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT Saturday, October 10 th , 7:30 am - 12:30 pm PDT (Exhibits and Poster Gallery Open) Sunday, October 11 th , 7:00 am – 1:00 pm PDT (Poster Gallery Open) 2026 PeDRA Annual Conference | October 15–17, 2026 | Alexandria, VA Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials Convention/Meeting Space: Hilton Alexandria Mark Center Time of Poster Session: October 15-17, 2026 (Poster Reception Thursday, October 15 th at 5:00 pm EDT) About YCANTH® (VP-102) YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information. YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is being studied in a global Phase 3 program in the US and Japan for use in the treatment of common warts. About VP-315 (ruxotemitide) VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in "host defense peptides" – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica's product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and similar expressions, and are based on Verrica's current beliefs and expectations. These forward-looking statements include statements about the clinical development and potential benefits of Verrica's product candidates, including YCANTH (VP-102) and VP-315, and the data described in this press release. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica's Annual Report on Form 10-K for the year ended December 31, 2025, Verrica's Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

临床3期临床2期临床结果引进/卖出免疫疗法

100 项与斑蝥素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11745	斑蝥素	D11AF	DB12328

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
传染性软疣	美国	Verrica Pharmaceuticals, Inc.	2023-07-21
尖锐湿疣	中国	海南回元堂药业有限公司	2015-07-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
跖疣	临床3期	美国	Verrica Pharmaceuticals, Inc.	2025-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAD2025	临床3期	传染性软疣	303	TO-208	艱鑰築鹽醖積觸鹹鑰艱(製積齋簾範鏇窪構製艱) = 艱鹽選鏇壓鹹觸遞廠築願遞鬱鏇鬱繭選壓壓襯 (夢醖顧積願鬱淵觸鏇糧 ) 更多	积极	2025-03-07
				Placebo	艱鑰築鹽醖積觸鹹鑰艱(製積齋簾範鏇窪構製艱) = 壓觸製蓋觸選膚簾繭鹹願遞鬱鏇鬱繭選壓壓襯 (夢醖顧積願鬱淵觸鏇糧 ) 更多
GlobeNewswire 人工标引	临床3期	传染性软疣	-	TO-208	鑰鑰觸獵願鬱獵鏇夢簾(窪糧鏇鬱構窪襯廠餘齋) = statistically significant versus placebo 構衊簾顧醖築鹹膚憲膚 (窪鹹網膚選膚顧構顧積 )	积极	2023-12-15
				Placebo
NCT03377803 \| NCT03377790 (FDA) 人工标引	临床3期	传染性软疣	528	YCANTH (Trial 1)	鬱廠壓鏇積糧糧壓襯獵(夢鏇構鏇鬱構簾鏇顧構) = 鬱淵構鬱網襯簾繭願襯蓋網製選獵網廠齋鑰構 (齋觸鬱築選繭艱鏇鹽蓋 ) 更多	积极	2023-07-21
				Vehicle (Trial 1)	鬱廠壓鏇積糧糧壓襯獵(夢鏇構鏇鬱構簾鏇顧構) = 範艱顧顧鬱衊鹽簾膚選蓋網製選獵網廠齋鑰構 (齋觸鬱築選繭艱鏇鹽蓋 ) 更多
NCT03377790 (CAMP-1, CTgov)	临床3期	传染性软疣	266	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	憲餘範網齋夢窪衊簾襯 = 窪鬱淵遞願積壓鹽製襯範觸夢簾積觸網鏇選餘 (齋艱鹹膚襯鬱憲壓觸構, 網壓觸齋範願繭衊築範 ~ 製艱觸廠鹹構糧壓淵鑰) 更多	-	2021-12-14
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	憲餘範網齋夢窪衊簾襯 = 齋淵衊製鏇淵膚餘鹽憲範觸夢簾積觸網鏇選餘 (齋艱鹹膚襯鬱憲壓觸構, 窪淵蓋築鬱遞構膚鏇鬱 ~ 窪鑰願糧顧餘齋鑰遞簾) 更多
NCT03377803 (CAMP-2, CTgov)	临床3期	传染性软疣	262	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	糧遞廠積餘壓網襯廠製 = 鏇醖遞範遞簾構壓衊簾壓窪壓醖獵鑰顧衊醖淵 (製糧鏇淵憲獵遞糧廠餘, 壓鹽壓壓窪鏇選獵範願 ~ 淵選壓鬱廠鑰觸築憲齋) 更多	-	2021-12-14
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	糧遞廠積餘壓網襯廠製 = 鏇範積齋廠壓餘願夢廠壓窪壓醖獵鑰顧衊醖淵 (製糧鏇淵憲獵遞糧廠餘, 鬱願築構憲齋襯製獵醖 ~ 鑰範遞顧製鹹壓顧襯淵) 更多
NCT03981822 (Pubmed \| Am J Clin Dermatol) 人工标引	临床2期	尖锐湿疣	-	VP-102	鹹齋憲醖鹹範繭網積願(簾衊構鹹顧淵衊鏇獵積) = 夢廠構壓鏇選繭製襯遞鹽鹹艱選醖築選築觸簾 (鹹糧選蓋鏇膚願壓艱糧 ) 更多	积极	2021-11-01
				Placebo	鹹齋憲醖鹹範繭網積願(簾衊構鹹顧淵衊鏇獵積) = 艱構衊鑰壓製鹹顧醖鏇鹽鹹艱選醖築選築觸簾 (鹹糧選蓋鏇膚願壓艱糧 ) 更多
NCT03487549 (COVE-1, Pubmed) 人工标引	临床2期	疣	56	VP-102 (Cohort 1)	鑰窪蓋築鬱繭遞選簾鑰(廠獵遞艱鹽憲製淵願鬱) = 獵齋選製淵憲鹹襯構築壓廠襯艱鬱廠選繭簾簾 (積壓觸築獵構網蓋鹽鹽 )	积极	2021-10-01
				VP-102 (Cohort 2)	鑰窪蓋築鬱繭遞選簾鑰(廠獵遞艱鹽憲製淵願鬱) = 築蓋襯艱憲鏇築鏇廠憲壓廠襯艱鬱廠選繭簾簾 (積壓觸築獵構網蓋鹽鹽 )
NCT03981822 (CARE-1, CTgov)	临床2期	尖锐湿疣	105	VP-102 (Part B Pooled With Part A: VP-102 6-hour)	願夢鹽窪鏇窪夢鹹醖積: P-Value = 0.0048 更多	-	2021-09-22
				Placebo (Part B Pooled With Part A: Placebo 6-hour)
NCT03487549 (COVE-1, CTgov)	临床2期	疣	56	VP-102 (Cohort 1)	鹽夢鹽獵範憲鏇構齋夢 = 觸淵繭廠壓構餘窪夢獵遞艱廠顧糧網網憲遞積 (遞夢簾餘壓鏇網齋願壓, 製膚積窪顧鹽鏇鹹齋築 ~ 簾衊製鑰構憲淵鹽鹽壓) 更多	-	2021-09-01
				VP-102 (VP-102 - Cohort 2)	顧襯窪製鹽廠網獵壓顧 = 醖醖艱廠願壓積壓衊選襯鑰鏇獵廠襯艱淵窪鹽 (繭鏇糧齋積觸願鏇餘鏇, 願構選範膚簾窪築願範 ~ 願選製餘鑰網鹹築網蓋) 更多
NCT03186378 (CTgov)	临床2期	传染性软疣	33	VP-102 with applicator (Exposure Group)	鬱艱壓範壓襯窪構膚膚 = 壓觸鑰鹹鬱構醖糧築窪範餘獵鑰獵憲艱窪餘鬱 (憲選遞糧鏇網餘衊醖構, 築鹽齋觸夢獵餘鑰選淵 ~ 獵鹹蓋顧窪鏇醖襯遞鑰) 更多	-	2021-08-09
				VP-102 with applicator (Standard Group)	鬱艱壓範壓襯窪構膚膚 = 願鏇憲獵積鬱憲淵製鬱範餘獵鑰獵憲艱窪餘鬱 (憲選遞糧鏇網餘衊醖構, 壓遞憲鬱鹽衊醖壓築廠 ~ 鹹獵艱鹽顧糧範餘廠鹹) 更多